The Second Middle East Lung Cancer Congress was a platform for discussing recent advances in understanding the pathophysiology of lung cancer. It aimed to enhance multidisciplinary collaboration between various specialties involved in the care of lung cancer patients.
At the end of the congress, attendees will be able to:
- Provide a multidisciplinary (MDT) approach to patients with lung cancer that involves the pathologists, pulmonologist, thoracic surgeon as well as Medical Oncologist; MDT is the new standard of approach and this conference aims on showing the benefit of this approach.
- Discuss recent advances in lung cancer therapy for both Non-small cell lung cancer and small cell lung cancer
- Better understand recent therapies mechanism of action and toxicities in new treatment modalities such as immunotherapy.
This conference invited Oncologists, Academicians, Physicians, Academic scientists, Radiologists, Chemo therapists, Industry professionals, Heads of the departments, Directors, Clinical Professionals, Young researchers, Postgraduates, Trainees and above all Lung cancer Researchers.